Key points are not available for this paper at this time.
Recent and detailed data regarding treatment quality of patients with AOC in the era of precision medicine are largely unknown in Germany. All German hospitals treating patients with ovarian cancer were asked to document prospectively all patients with first diagnosis in the third quarter in 2021. Details of tumor, treatment and outcome were documented. Here, we report tumor and treatment characteristics. In total, 598 pts with AOC were documented. The primary debulking surgery (PDS) rate was 429/598 (71.7%) and complete resection (CR) at PDS was achieved in 252/429 pts (58.7%), 92/598 pts (15.4%) had interval debulking surgery and 77/598 pts (12.9%) had no surgery. In total, 514/598 pts (86.0%) were treated with chemotherapy. 490/514 (95.3%) received carboplatin/paclitaxel and 401/514 (78.0%) received additional maintenance therapy. 470 patients had high-grade histology and were treated with chemotherapy. The BRCA testing rate in this population was 390/470 (83.0%) and HRD testing rate was 245/470 (52.1%). In total, 90 of 390 tested patients were BRCA-positive (23.1%) and 101/245 patients were HR deficient (41.2%). BRCA+ patients were treated with bevacizumab/PARPi in 58.9%, PARPi single agent in 31.1%. The rates in BRCAwt/HRd were 62.9% and 12.0%, respectively. HRp tumors were treated mainly with bevacizumab (70.8%) or by PARPi in 15.4%. BRCAwt/HRD unknown patients were treated mainly with bevacizumab (35.8%) or PARPi (30.5%). Patients who were not tested (15.8%) were mainly treated with chemotherapy only (58.0%) and bevacizumab (35.8%). The rates of chemo only patients in the other subgroups varied between 2.2% and 22.1%. Most patients in Germany with AOC are treated with primary surgery followed by chemotherapy including a maintenance therapy. The rates of BRCA and HRD testing are high and PARPi in primary OC are often used already after a short period after approval in Germany.
Harter et al. (Sat,) studied this question.